Investoren-Telefonkonferenz Rivaroxaban-Review zum World Congress of Cardiology

Dienstag, 5. September 2006
Beginn: ca. 18.00 Uhr MEZ (16:00 Uhr GMT)


Dr. Gunnar Riemann
Leiter der Division Pharma

Dr. Frank Misselwitz
Leiter Therapeutic Area Cardiovascular, Global Clinical Development

Die Audio-Aufzeichnung dieser Veranstaltung ist nicht mehr verfügbar.

World Congress of Cardiology 2006 Abstracts zu Rivaroxaban:

Once-daily treatment with an oral, direct Factor Xa inhibitor - rivaroxaban (BAY 59-7939) - in patients with acute, symptomatic deep vein thrombosis. The EINSTEIN-DVT dose-finding study (Abstract P4568)

Treatment of acute, symptomatic, proximal deep vein thrombosis with the oral, direct Factor Xa inhibitor rivaroxaban (BAY 59-7939) - the ODIXa-DVT dose-ranging study (Abstract P4569)

Antithrombotic effects of rivaroxaban - an oral, direct Factor Xa inhibitor - in animal models of arterial and venous thrombosis: comparison with enoxaparin, an antithrombin-dependent anticoagulant (Abstract P4571)

Letzte Änderung: 09. Januar 2014 Copyright © Bayer AG